(Reuters Health)—In states that expanded either their Medicaid programs or private insurance options for low-income Americans, beneficiaries used more outpatient and preventive care and less emergency care. They also had better subjective overall health, compared with low-income residents of states with no expanded coverage. All states participate in Medicaid, a partnership with the federal government…
Search results for: hip OA
How to Leverage Patient Satisfaction
Medicare and other insurers are using patient satisfaction to determine provider payment. But according to one expert, rheumatologists who look at their practice with a critical eye, listen and ask their patients the right questions may improve their patient relationships and their practice…
The ACR Continues Fight to Block Medicare Part B Demo Project: Rule Expected in Fall 2016
The ACR will seek Congressional action if the Medicare Part B demonstration project proposed by the Centers for Medicare & Medicaid Services (CMS) is not significantly altered by the agency. Today, Medicare Part B generally pays physicians and hospital outpatient departments the average sales price of a drug, plus a 6% add-on, minus reductions required…
Milestones of Rheumatology Education
In 2013, a collaboration began to advance the training and assessment of fellows. The result: A uniform set of educational reporting milestones for all internal medicine subspecialties was developed. Key stakeholders were then asked to develop a list of entrustable professional activities (EPAs), a set of responsibilities any specialist should be able to perform, for their subspecialties. The ACR’s Next Accreditation System working group developed 14 EPAs for rheumatology…
From the Expert: Musculoskeletal Ultrasound Training Benefits Rheumatology Practices & Patients
Eugene Kissin, MD, says the use of musculoskeletal ultrasound can help rheumatologists diagnose and treat disease. Getting the proper training is critical. USSONAR is a training resource that can help…
New FDA Warnings: Patients on SGLT2 Inhibitors at Risk of Acute Kidney Injury & Loperamide Abuse on the Rise
The FDA is strengthening its warning that canagliflozin and dapagliflozin may increase the risk for acute kidney injury in some patients. Also, the FDA has issued a warning that patients should not exceed recommended doses of loperamide due to increased risks of serious cardiac events…
Ethics Forum: Unexpected Ethical Issues in Private Practice, Clinical Research
Ethical issues that arise in the average rheumatology practice and in clinical research are often straightforward. The AMA Code of Medical Ethics and the Office Practice and Procedures Manual offer useful information.1 In research, the Protocol and Investigators Agreement spells out who you can enroll and how the trial must be conducted. But still—even when…
Rheumatology Coding Corner Question: Physical Examination with Infliximab Infusion
A 12-year-old male established patient with inflammatory bowel disease with associated juvenile spondyloarthropathy returns to the office for a follow-up visit for his infliximab infusion. The patient reports moderate pain in his right hip after walking for extended periods of time or after sports activities. He denies any other joint pain and denies any joint…
How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis
The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…
Rheumatology Drug Updates: Labeling for Fluoroquinolones; FDA to Review Benzhydrocodone/Acetaminophen Combination
FDA Restricts Fluoroquinolone Use The U.S. Food and Drug Administration (FDA) has twice previously communicated safety information about systemic fluoroquinolones—in August 2013 and July 2008. The safety issues of this medication class described in its latest Drug Safety Communication were also discussed at a November 2015 FDA Advisory Committee meeting.1 The FDA is now advising…
- « Previous Page
- 1
- …
- 223
- 224
- 225
- 226
- 227
- …
- 337
- Next Page »